Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00II. Q1 2026 Revenue and Financial Performance
MRNA logo

Moderna’s International Sales Surge 260% Amid $878 Million Litigation Charge

MRNA8-KFiling Date: 5/1/2026
Moderna, Inc.
Description

What this story covers

Moderna reported a 260 percent revenue increase driven by international vaccine sales, despite a 1.3 billion dollar net loss fueled by a major litigation settlement. With 7.5 billion dollars in cash, the company is pivoting toward a diversified pipeline in oncology and flu.

Story snapshot

CompanyModerna, Inc.
TickerMRNA
VariantStandard detailed
Duration5:34
Filing type8-K
PeriodAnnual 2026
IndustryHealthcare & Pharmaceuticals
Accession0001682852-26-000057
Sources1

Full Story Script

Content not available for this story.

Primary Sources

sec_filing8-KView on SEC.gov →

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in